title: Sonodynamically-induced antitumor effect of mono-l-aspartyl chlorin e6 (NPe6).
abstract: BACKGROUND
  The sonodynamically-induced in vitro and in vivo antitumor effects of mono-l-aspartyl chlorin e6 (NPe6) was investigated.
  
  
  METHODS
  Both in vitro and in vivo antitumor effects were tested in combination with ultrasound at 2 MHz.
  
  
  RESULTS
  The rate of ultrasonically-induced damage on isolated sarcoma 180 cells in air-saturated suspension was enhanced two-fold with 80 μM NPe6. The co-administration of 25 mg/kg NPe6 followed by ultrasonic exposure at 2 MHz suppressed the growth of implanted colon 26 cell tumors at an intensity at which ultrasound alone showed only a slight antitumor effect.
  
  
  CONCLUSIONS
  These in vitro and in vivo results suggest that NPe6 is a potential sensitizer for sonodynamic tumor treatment. The enhancement of cell damage by NPe6 was significantly inhibited by histidine, which may suggest reactive oxygen species plays a primary role in sonodynamically-induced antitumor effect.
authors.affiliation: Yokohama College of Pharmacy, 601 Matano-cho, Totsuka-ku, Yokohama, Kanagawa 245-0066, Japan. n.yumita@hamayaku.ac.jp
authors.forename: Nagahiko
authors.initials: N
authors.lastname: Yumita
authors.forename: Yumiko
authors.initials: Y
authors.lastname: Iwase
authors.forename: Koji
authors.initials: K
authors.lastname: Nishi
authors.forename: Toshihiko
authors.initials: T
authors.lastname: Ikeda
authors.forename: Hajime
authors.initials: H
authors.lastname: Komatsu
authors.forename: Toshio
authors.initials: T
authors.lastname: Fukai
authors.forename: Kenji
authors.initials: K
authors.lastname: Onodera
authors.forename: Hiroyoshi
authors.initials: H
authors.lastname: Nishi
authors.forename: Kazuyoshi
authors.initials: K
authors.lastname: Takeda
authors.forename: Shin-Ichiro
authors.initials: S
authors.lastname: Umemura
authors.forename: Kazuho
authors.initials: K
authors.lastname: Okudaira
authors.forename: Yasunori
authors.initials: Y
authors.lastname: Momose
mesh_terms: D000818:Animals; D000970:Antineoplastic Agents / Q000494:pharmacology*; D003131:Combined Modality Therapy; D008297:Male; D051379:Mice; D008807:Mice, Inbred BALB C; D008813:Mice, Inbred ICR; D011166:Porphyrins / Q000494:pharmacology*; D012510:Sarcoma 180 / Q000188:drug therapy / Q000628:therapy*; D014464:Ultrasonic Therapy
chemical_list: D000970:Antineoplastic Agents; D011166:Porphyrins; C053434:Talaporfin